13F Holdings
中文EN

MNKD MANNKIND CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 899460 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.7%
TTM net income YoY-356.0%
TTM EPS YoY-340.0%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—

Margins

Gross margin88.6%
Operating margin-2.9%
Net margin-18.1%
FCF margin-19.0%
EBITDA margin1.1%

Returns

ROE—
ROA-12.3%
ROIC (approx.)-10.5%
Asset turnover0.68x

Leverage & solvency

Liabilities / assets105.2%
Debt / equity—
Current ratio2.22x
Interest coverage-0.34x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$348.97M$285.50M$198.96M$99.77M$75.44M
Cost of revenue$26.80M$17.43M$20.86M$16.00M$16.83M
Gross profit$322.17M$268.07M$178.10M$83.77M$58.61M
R&D expense$66.35M$45.89M$31.28M$19.72M$12.31M
SG&A expense$144.13M$94.33M$94.31M$91.47M$31.89M
Operating income$38.80M$72.59M$8.68M-$64.11M-$47.02M
Interest expense$13.83M$11.98M$15.15M$15.01M$15.20M
Pretax income$1.41M$30.52M-$10.38M-$87.40M-$80.93M
Income tax-$4.46M$2.93M$1.56M$0$0
Net income$5.86M$27.59M-$11.94M-$87.40M-$80.93M
EBITDA$51.09M$79.96M$13.21M-$60.78M-$45.04M
EPS (basic)0.020.10-0.04-0.34-0.32
EPS (diluted)0.020.10-0.04-0.34-0.32
Weighted avg. shares (diluted)314.11M283.84M267.01M257.09M249.24M
Balance sheet
Cash & equivalents$74.88M$46.34M$238.48M$69.77M$124.18M
Short-term investments$96.46M$150.92M$56.62M$101.08M$79.93M
Receivables$38.37M$11.80M$14.90M$16.80M$4.74M
Inventory$35.31M$27.89M$28.55M$21.77M$7.15M
Current assets$291.58M$268.31M$373.39M$234.90M$219.49M
PP&E, net$82.42M$85.36M$84.22M$45.13M$36.61M
Goodwill$67.59M$1.93M$1.93M$2.43M—
Intangibles$5.07M$5.26M$1.07M$1.15M—
Total assets$792.18M$393.84M$475.20M$295.28M$321.16M
Current liabilities$171.03M$81.84M$104.12M$67.30M$48.35M
Long-term debt$354.64M$36.05M$268.70M$273.49M$281.20M
Total debt$354.64M$36.05M$268.70M$273.49M$281.20M
Total liabilities$843.20M$472.66M$721.37M$545.82M$530.51M
Shareholders' equity-$51.02M-$78.82M-$246.17M-$250.54M-$209.35M
Net debt$279.76M-$10.29M$30.22M$203.72M$157.02M
Shares outstanding307.83M302.96M270.03M263.79M251.48M
Cash flow statement
Operating cash flow$18.25M$42.51M$34.09M-$80.68M-$61.71M
Capital expenditure$4.57M$9.69M$42.44M$7.59M$11.47M
Free cash flow$13.69M$32.82M-$8.35M-$88.27M-$73.17M
Investing cash flow-$304.80M-$96.65M-$1.99M$4.87M-$151.54M
Financing cash flow$315.10M-$137.27M$136.61M$21.39M$270.27M
Depreciation & amortization$12.28M$7.37M$4.54M$3.33M$1.99M
Stock-based compensation$24.20M$21.36M$17.65M$13.45M$12.20M

Free plan shows the latest 5 periods; Pro shows all 33 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.